Joaquin Martinez Arraras Caro, MD
Cardiovascular Disease · Amarillo, TXNPI 1598730269
Payments from drug & device makers
Across 655 payments — averaging $1888.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$630K
- Novartis$305K
- Eli Lilly$111K
- Abbott$44K
- American Regent$40K
- Amgen$34K
- plus $74K from 29 others
Across 3 payments — averaging $10,758 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$32K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 38 | $629,558 |
| Novartis | 32 | $304,951 |
| Eli Lilly | 5 | $110,955 |
| Abbott | 85 | $43,562 |
| American Regent | 5 | $39,625 |
| Amgen | 42 | $33,893 |
| Esperion Therapeutics, Inc. | 22 | $27,724 |
| Amarin Pharma, Inc. | 41 | $27,088 |
| Edwards Lifesciences | 224 | $8,000 |
| Pfizer | 16 | $5,365 |
| Abiomed | 22 | $1,569 |
| Medtronic(2 entities) | 11 | $1,142 |
| E.r. Squibb & Sons, L.L.C. | 50 | $1,049 |
| Boston Scientific | 9 | $670 |
| AstraZeneca | 12 | $322 |
| Shockwave Medical, Inc | 2 | $278 |
| Biotronik Inc. | 3 | $198 |
| Merck | 11 | $182 |
| Cordis US CORP. | 3 | $160 |
| Cvrx, Inc. | 1 | $103 |
| Novo Nordisk | 5 | $88 |
| Philips North America LLC | 1 | $83 |
| Boehringer Ingelheim | 2 | $37 |
| Galderma Laboratories, L.p. | 2 | $32 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
| BD | 1 | $23 |
| Penumbra, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| CSL Behring | 1 | $16 |
| Biosense Webster, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $12 |
How this compares
$1,236,837 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Amarillo
- David BrabhamAmarillo$11.5M
- Alfred ChuAmarillo$1.3M
- Rajesh NambiarAmarillo$574K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.